Loading stock data…
ESPR
$3.11+1.11 (+55.50%)
Market ClosedLast close May 1
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Esperion Therapeutics, Inc. in the Healthcare sector is trading at $3.11. The stock is currently 26% below its 52-week high of $4.18, remaining 11.5% above its 200-day moving average. Technical signals show overbought RSI of 74 and bullish MACD crossover, explaining why ESPR maintains its current momentum and trend strength. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 74) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.11
Potential Upside
5%
Whystock Fair Value$3.27
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Hold
Mean target$3.82+22.8%
Range$3.16 – $5.16
Fundamentals
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXL...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$498.08M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.17
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
7.51%
Volume
Today's trading volume
182.32M
Recent News
ARCHIMED to acquire Esperion Therapeutics in $1.1 billion deal
Shareholders will receive $3.16 per share in cash at closing — a 58% premium — plus contingent payments of up to $100 million
Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal
Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast cancer medicine.
Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference
Esperion Therapeutics (NASDAQ:ESPR) outlined its commercial progress and strategic priorities at Needham & Company’s 25th Annual Healthcare Conference, highlighting revenue growth, new clinical and guideline tailwinds for its cholesterol franchise, and the recent acquisition of Corstasis Therape
Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?
Karyopharm Therapeutics (KPTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.